Biotinylated Human PD-1(recommended for biopanning) (PD1-H82E4) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # NP_005009.2).
N-terminal Sequence Analysis: Leu 25
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 18.6 kDa. The protein migrates as 30-48 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
PD1-H82E4 works best for experiments that test the binding between PD-1 and candidate antibodies, such as biopanning and other relevant assays.
This product is NOT suitable for testing PD1-PDL1 binding. For this type of application, we strongly recommend you to choose PD1-H82F2 as an alternative.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human PD-1(recommended for biopanning) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Measured by its binding ability in a functional ELISA against immobilized Nivolumab (0.2 μg/well). The linear range is 0.8-6 ng/mL (QC tested).
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
- (1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
- (2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
- (3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
- (4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
- (5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
- (6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
专利使用说明（Limited Use License）
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.